Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multidrug chemotherapy in osteosarcoma

W W Sutow

    Clinical Orthopaedics and Related Research
    |November 1, 1980
    PubMed
    Summary
    This summary is machine-generated.

    This review details the evolution of adjuvant chemotherapy for osteosarcoma, incorporating drug efficacy, patient tolerance, and pharmacokinetic data. The current COMPADRI-V regimen shows a 79% three-year survival rate.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Medical survey of Rongelap people eight years after exposure to fallout.

    T. Brookhaven National Laboratory·2014
    Same author

    Chemotherapy-induced histologic changes in Wilms' tumors.

    Pediatric pathology·1984
    Same author

    Renal cell carcinoma in children.

    Medical and pediatric oncology·1983
    Same author

    [Experimental study on pharmacokinetics of methotrexate and its metabolite (7-hydroxy-methotrexate) in tissue].

    Gan to kagaku ryoho. Cancer & chemotherapy·1982
    Same author

    Prognosis in children with Wilms' tumor metastases prior to or following primary treatment: results from the first National Wilms' Tumor Study (NWTS-1).

    American journal of clinical oncology·1982
    Same author

    Three-year relapse-free survival rates in childhood rhabdomyosarcoma of the head and neck: report from the Intergroup Rhabdomyosarcoma Study.

    Cancer·1982
    Same journal

    Impact Microindentation Evaluates Bone Strength, Bone Quality, and Fracture Susceptibility Across Skeletal Sites: A Cadaver Study.

    Clinical orthopaedics and related research·2026
    Same journal

    What Is the Effect of Robot Reduction in Displaced Pelvic Fractures? A Multicenter Randomized Clinical Trial.

    Clinical orthopaedics and related research·2026
    Same journal

    CORR Insights®: Acute or Delayed TKA for Tibial Plateau Fracture? An Observational Study From the Swedish Arthroplasty Register.

    Clinical orthopaedics and related research·2026
    Same journal

    Reply to the Letter to the Editor: Guest Editorial: Recalling a Recall.

    Clinical orthopaedics and related research·2026
    Same journal

    Radial Head Fractures Cluster in the Anterolateral and Anteromedial Quadrants and Do Not Correlate With Coronoid Fracture Types.

    Clinical orthopaedics and related research·2026
    Same journal

    Reduced Cerebellar Activation With Eyes Closed Is Associated With Delayed Peroneal Reaction Time in Patients With Chronic Ankle Instability.

    Clinical orthopaedics and related research·2026
    See all related articles

    Area of Science:

    • Oncology
    • Pharmacology
    • Surgical Oncology

    Background:

    • Osteosarcoma treatment has evolved over 19 years.
    • Adjuvant chemotherapy is a critical component of osteosarcoma management.

    Purpose of the Study:

    • To review the evolution of adjuvant chemotherapy programs for osteosarcoma.
    • To highlight key concepts and outcomes of the COMPADRI-V regimen.

    Main Methods:

    • Review of historical treatment data and program evolution.
    • Incorporation of pharmacokinetic data and patient tolerance assessments.
    • Analysis of intensified high-dose methotrexate and Adriamycin regimens with preoperative chemotherapy.

    Main Results:

    • The COMPADRI-V program integrates demonstrated antitumor activity, patient tolerance, and pharmacokinetic data.

    Related Experiment Videos

  • The current regimen facilitates limb-salvage procedures.
  • Achieved an overall survival rate of 79% at three years for osteosarcoma patients.

    • Conclusions:

    • The COMPADRI-V regimen represents a successful advancement in osteosarcoma adjuvant chemotherapy.
    • The integration of multiple treatment optimization strategies has improved patient survival outcomes.